Sugi Predict

Sugi Predict / Compounds / SCHEMBL1787264

SCHEMBL1787264

SCHEMBL1787264

COC(=O)c1cc(N)c(OC)cc1Cl

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 6/20 0.66
▸ KDM4E B2RXH2 6/20 0.59
▸ ABL1 P00519 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ ALDH1A1 P00352 7/20 0.49
▸ HSD17B10 Q99714 3/20 0.49
▸ CFTR P13569 1/20 0.49
▸ HTT P42858 2/20 0.46
▸ HPGD P15428 4/20 0.45
▸ GLA P06280 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ CASP7 P55210 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ MAPK13 O15264 1/20 0.44
▸ MAPK12 P53778 1/20 0.44
▸ MAPK11 Q15759 1/20 0.44
▸ MAPK14 Q16539 1/20 0.44
▸ NQO2 P16083 1/20 0.43
▸ LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15797714 0.93 GAA (0.66) GAAKDM4EABL1POLBALDH1A1
SCHEMBL31305136 0.85 KDM4E (0.72) GAAKDM4EABL1POLBALDH1A1
SCHEMBL9793695 0.85 GAA (0.59) GAAKDM4EABL1POLBALDH1A1
SCHEMBL11775476 0.84 GAA (0.53) GAAKDM4EPOLBALDH1A1HTT
SCHEMBL1786323 0.84 GAA (0.51) GAAKDM4EABL1POLBALDH1A1
SCHEMBL1785666 0.84 GAA (0.51) GAAKDM4EABL1ALDH1A1HSD17B10
SCHEMBL8902306 0.84 GAA (0.67) GAAKDM4EABL1POLBALDH1A1
SCHEMBL30697733 0.84 GAA (0.67) GAAKDM4EABL1ALDH1A1HSD17B10
SCHEMBL1787222 0.84 GAA (0.67) GAAKDM4EABL1ALDH1A1HSD17B10
SCHEMBL2897626 0.84 GAA (0.62) GAAKDM4EABL1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-RE50527-E1 Covalent inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-08-12 — — US disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed
EP-3401314-B1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-11-08 — — EP disclosed
US-10919850-B2 Covalent inhibitors of KRas G12C ARAXES PHARMA LLC (US) 2021-02-16 — — US disclosed
US-10919850-B2 Covalent inhibitors of KRas G12C ARAXES PHARMA LLC (US) 2021-02-16 — — US disclosed
EP-3193851-B1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2020-10-21 — — EP disclosed
US-20190262342-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2019-08-29 — — US disclosed
US-20190262342-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2019-08-29 — — US disclosed
US-10273207-B2 Covalent inhibitors of kras G12C ARAXES PHARMA LLC (US) 2019-04-30 — — US disclosed
WO-2014152588-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2014-09-25 — — WO disclosed
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2014-09-25 — — US disclosed
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 — — US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 — — EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 — — US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 — — US disclosed
CN-101883762-A Benzothiazoles as modulators of growth hormone releasing hormone receptors ASTRAZENECA AB 2010-11-10 — — CN disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 — — EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 — — US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 GAA 2767/4885KDM4E 810/4885ABL1 57/4885
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R GAA 1879/4885KDM4E 1188/4885ABL1 1364/4885
US-20140288045-A1 COVALENT INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS GAA 1747/4885KDM4E 1936/4885ABL1 111/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R GAA 402/4885KDM4E 3215/4885ABL1 898/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R GAA 549/4885KDM4E 3524/4885ABL1 983/4885
US-20190262342-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS GAA 2526/4885KDM4E 4202/4885ABL1 241/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R GAA 1879/4885KDM4E 1188/4885ABL1 1364/4885
US-10919850-B2 Covalent inhibitors of KRas G12C KRAS, NRAS, HRAS GAA 1747/4885KDM4E 1936/4885ABL1 111/4885
US-10273207-B2 Covalent inhibitors of kras G12C KRAS, NRAS, HRAS GAA 1747/4885KDM4E 1936/4885ABL1 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.